T3	total-participants 682 686	6459
T4	age 698 712	55 to 81 years
T5	control 731 738	placebo
T7	total-participants 904 908	7765
T8	location 1109 1171	Asia and the Pacific, Europe, North America, and South America
T10	outcome 1625 1647	incident breast cancer
T11	outcome 1760 1781	rate of breast cancer
T12	cv-bin-percent 1790 1794	1.5%
T13	cv-bin-abs 1800 1802	46
T14	iv-bin-percent 1829 1833	1.8%
T19	cv-bin-percent 1973 1977	0.8%
T20	iv-bin-percent 2012 2016	0.9%
T6	iv-bin-abs 1839 1841	57
T1	intervention 117 148	alendronate and zoledronic acid
